HWHG(SH:600079) Zheng Quan Shi Bao Wang·2026-01-05 08:32Core Viewpoint - ST Renfu (600079) has received approval from the National Medical Products Administration for the clinical trial of HW221043 tablets, a new molecular entity aimed at treating advanced solid tumors, with no similar drugs approved in the market to date [1]. Group 1: Company Developments - The wholly-owned subsidiary of ST Renfu, Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd., has been granted the clinical trial approval for HW221043 tablets [1]. - HW221043 tablets represent a self-developed new molecular entity by the company [1]. - The total research and development investment for HW221043 tablets has reached approximately 24 million yuan [1]. Group 2: Market Context - There are currently no similar drugs approved for market use, indicating a potential unique position for HW221043 in the treatment of advanced solid tumors [1].